Lv5
1155 积分 2021-05-28 加入
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
19天前
已完结
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
1个月前
已完结
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
7个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
7个月前
已完结
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
7个月前
已完结
Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells
8个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
9个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
9个月前
已完结
Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4
9个月前
已完结
Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells
9个月前
已完结
皖公网安备34019202002308
